Bicara Therapeutics CEO Claire Mazumdar Exercises Stock Options and Sells Shares

This Form 4 filing reports that Claire Mazumdar, Chief Executive Officer and Director of Bicara Therapeutics Inc. (BCAX), exercised stock options and sold shares in April 2026. On April 16, Mazumdar exercised options for 8,226 shares at $4.4369 per share, 7,454 shares at $3.7898 per share, and 7,080 shares at $5.4537 per share. On April 20, she exercised options for 15,000 shares at $3.7898 per share and immediately sold 15,000 shares at a weighted average price of $23.6097 per share. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, Mazumdar's direct ownership stands at 362,152 shares of common stock. The options were part of various equity incentive plans with vesting schedules spanning quarterly installments through 2023.